Research Analysts Issue Forecasts for Fennec Pharmaceuticals Inc.’s FY2025 Earnings (TSE:FRX)

Fennec Pharmaceuticals Inc. (TSE:FRX) – Stock analysts at Capital One Financial boosted their FY2025 earnings per share estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Thursday, May 2nd. Capital One Financial analyst N. Quibria now expects that the biopharmaceutical company will post earnings per share of $0.97 for the year, up from their prior forecast of $0.96. The consensus estimate for Fennec Pharmaceuticals’ current full-year earnings is $0.42 per share. Capital One Financial also issued estimates for Fennec Pharmaceuticals’ FY2026 earnings at $1.63 EPS and FY2028 earnings at $4.63 EPS.

Fennec Pharmaceuticals Stock Performance

Shares of FRX stock opened at C$12.65 on Monday. The company’s fifty day simple moving average is C$13.58 and its 200-day simple moving average is C$12.96. The company has a current ratio of 3.56, a quick ratio of 10.17 and a debt-to-equity ratio of 881.09. Fennec Pharmaceuticals has a 52 week low of C$9.27 and a 52 week high of C$15.43. The company has a market cap of C$342.82 million, a PE ratio of -15.43 and a beta of 0.40.

Fennec Pharmaceuticals (TSE:FRX) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported C($0.14) EPS for the quarter, missing the consensus estimate of C$0.02 by C($0.16). Fennec Pharmaceuticals had a negative net margin of 75.50% and a negative return on equity of 1,005.59%. The business had revenue of C$13.25 million during the quarter, compared to analysts’ expectations of C$12.88 million.

Insider Buying and Selling at Fennec Pharmaceuticals

In related news, Senior Officer Adrian J. Haigh bought 22,222 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was bought at an average price of C$2.31 per share, with a total value of C$51,332.82. In related news, Senior Officer Robert Christopher Andrade sold 13,975 shares of the firm’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of C$10.90, for a total transaction of C$152,345.67. Also, Senior Officer Adrian J. Haigh purchased 22,222 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were purchased at an average cost of C$2.31 per share, for a total transaction of C$51,332.82. Insiders have sold 39,112 shares of company stock valued at $390,926 over the last three months. 14.60% of the stock is owned by company insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.